Telephone
61.3.9349.4906
Address
Suite 4 Level 14 350 Collins Street Melbourne, Victoria (VIC) 3000
Description
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.02
Trade Value (12mth)
AU$44,891.00
1 week
0%
1 month
-6.67%
YTD
55.56%
1 year
366.67%
All time high
1.50
EPS 3 yr Growth
-42.20%
EBITDA Margin
N/A
Operating Cashflow
-$13m
Free Cash Flow Return
-68.60%
ROIC
-104.00%
Interest Coverage
N/A
Quick Ratio
3.50
Shares on Issue (Fully Dilluted)
5313m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.50
Date | Announcements |
---|---|
15 August 25 |
Notification regarding unquoted securities - ATH
×
Notification regarding unquoted securities - ATH |
15 August 25 |
Notification regarding unquoted securities - ATH
×
Notification regarding unquoted securities - ATH |
04 August 25 |
Response to ASX Query Letters
×
Response to ASX Query Letters |
31 July 25 |
Updated Corporate Presentation
×
Updated Corporate Presentation |
30 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
28 July 25 |
Change in substantial holding
×
Change in substantial holding |
28 July 25 |
Positive ATH434 Results from Open-Label Phase 2 Trial in MSA
×
Positive ATH434 Results from Open-Label Phase 2 Trial in MSA |
24 July 25 |
Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE
×
Peer-Reviewed Publication on Novel MRI Endpoint from bioMUSE |
21 July 25 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
17 July 25 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
14 July 25 |
Response to ASX Price Query
×
Response to ASX Price Query |
07 July 25 |
Change in substantial holding
×
Change in substantial holding |
03 July 25 |
Notification regarding unquoted securities - ATH
×
Notification regarding unquoted securities - ATH |
30 June 25 |
Notification of cessation of securities - ATH
×
Notification of cessation of securities - ATH |
23 June 25 |
Alterity CEO to Provide Corporate Update on ATH434
×
Alterity CEO to Provide Corporate Update on ATH434 |
23 May 25 |
Change in substantial holding
×
Change in substantial holding |
12 May 25 |
Change in substantial holding
×
Change in substantial holding |
12 May 25 |
Alterity Prominently Featured at International MSA Congress
×
Alterity Prominently Featured at International MSA Congress |
07 May 25 |
Alterity Phase 2 Data to be Featured at MSA Congress
×
Alterity Phase 2 Data to be Featured at MSA Congress |
05 May 25 |
Alterity Granted U.S. FDA Fast Track Designation for ATH434
×
Alterity Granted U.S. FDA Fast Track Designation for ATH434 |
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 25 |
Change of Director's Interest Notice x 3
×
Change of Director's Interest Notice x 3 |
28 April 25 |
Alterity Phase 2 Presentation at MSA Symposium 2025
×
Alterity Phase 2 Presentation at MSA Symposium 2025 |
22 April 25 |
Updated Corporate Presentation
×
Updated Corporate Presentation |
22 April 25 |
Application for quotation of securities - ATH
×
Application for quotation of securities - ATH |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.